Immutep Ltd (AU:IMM) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immutep Limited has released promising results from its INSIGHT-003 trial, showcasing the efficacy of its immunotherapy treatment, eftilagimod alpha, in combination with pembrolizumab and chemotherapy for non-small cell lung cancer. The trial demonstrated a median overall survival of 32.9 months and a 24-month survival rate of 81%, significantly outperforming historical controls. The positive safety profile and improved response rates underscore the potential of efti to enhance existing cancer treatments.
For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.